Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 197

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 197
---
 Advisory vote: Approval of Composition of the new Senior Management following the Merger (PROPOSAL 10) According to Section 6.2.8 of the Merger Agreement, the current officers of the Company are required to resign from their positions (other than Eric Konofal who shall remain in part -timepositions) prior to the effectiveness of the Merger and the Company is required to appoint the executive officers of Kadimastem as executive officers of the Company upon the effective time of the Merger. Accordingly, at the extraordinary shareholders’ meeting, shareholders of the Company will be asked, on an advisory basis, to approve Mr. Ronen Twito as Executive Chairman and Chief Executive Officer, Prof. Michel Revel, MD, PhD, as Chief Scientific Officer, Mr. Kfir Molakandov, PhD, as Vice President Research and Development and Mr. Ariel Revel, MD, as Director of Medical Affairs. NLS is holding a shareholder advisory vote on the appointment of new executive officers. A resolution resulting from such an advisory vote lacks legal binding effect under Swiss law. Therefore, the NLS Board retains full decision -makingauthority and may proceed with a transaction even if shareholders vote against Proposal 10. The NLS Board shall nonetheless consider the shareholders’ vote on Proposal 10 in its decision -makingprocess. Biographical information concerning Mr. Ronen Twito, Prof. Michel Revel, Mr. Kfir Molakandov and Mr. Ariel Revel is set forth below: Ronen Twito CPA, Executive Chairman & Chief Executive Officer Mr.Ronen Twito, as served as Kadimastem’s Executive Charmian of the Board of Director since December 2020 and its Chief Executive Officer since December 2024. Mr.Twito brings over two decades of executive leadership experience in the biotech and high -techsectors, across both Nasdaq and TASE listed companies. Mr.Twito also served as the Chairman of the board of Bubbles Intergroup Ltd (TASE: “BBLS”) since January 2022. From March 2019 until August 2021, he served as an Independent Director at Mer Telemanagement Solutions Ltd. (Nasdaq: “MTSL”). From November 2015 to March 2017 Mr.Ronen Twito served as Deputy Chief Executive Officer and CFO at Cellect Biotechnology Ltd. (Nasdaq: “APOP”). From May 2014 until November 2015, he served as Vice President of Finance at BioBlast